BR112015017463A2 - formulação em pó - Google Patents
formulação em póInfo
- Publication number
- BR112015017463A2 BR112015017463A2 BR112015017463A BR112015017463A BR112015017463A2 BR 112015017463 A2 BR112015017463 A2 BR 112015017463A2 BR 112015017463 A BR112015017463 A BR 112015017463A BR 112015017463 A BR112015017463 A BR 112015017463A BR 112015017463 A2 BR112015017463 A2 BR 112015017463A2
- Authority
- BR
- Brazil
- Prior art keywords
- raw material
- powder
- liquid
- thrombin
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
resumo patente de invenção para: "formulação em pó". a presente invenção refere-se a composições em pó estéreis adequadas para uso médico que compreendem trombina e fibrinogênio, e a métodos para produzir as mesmas, em que o pó de trombina é produzido a partir de uma matéria-prima líquida, em que a matéria-prima compreende uma solução ou uma suspensão de trombina, de preferência, uma solução, em que o pó é produzido pela remoção de líquido por um processo selecionado a partir de secagem por aspersão asséptica ou secagem em leito fluidizado asséptica, e em que o pó resultante da remoção de líquido da matéria-prima exibe pelo menos 80% da potência ou atividade de trombina da matéria-prima líquida, e em que o pó de fibrinogênio é produzido pela remoção de líquido de uma matéria-prima, em que a matéria-prima compreende uma solução ou uma suspensão de fibrinogênio, de preferência, uma solução, por secagem por aspersão asséptica ou secagem em leito fluidizado asséptica, e em que a dita composição é embalada como um produto farmacêutico final estéril para uso médico.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361774143P | 2013-03-07 | 2013-03-07 | |
| US201361774125P | 2013-03-07 | 2013-03-07 | |
| GBGB1304145.4A GB201304145D0 (en) | 2013-03-07 | 2013-03-07 | Powder formulation |
| GBGB1304146.2A GB201304146D0 (en) | 2013-03-07 | 2013-03-07 | Powder formulation |
| GBGB1313909.2A GB201313909D0 (en) | 2013-08-02 | 2013-08-02 | Powder formulation |
| PCT/EP2014/054477 WO2014135689A2 (en) | 2013-03-07 | 2014-03-07 | Powder formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015017463A2 true BR112015017463A2 (pt) | 2017-07-11 |
| BR112015017463A8 BR112015017463A8 (pt) | 2017-11-28 |
Family
ID=51492058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015017463A BR112015017463A8 (pt) | 2013-03-07 | 2014-03-07 | Formulação em pó |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160015792A1 (pt) |
| EP (1) | EP2964252A2 (pt) |
| JP (1) | JP2016510059A (pt) |
| CN (1) | CN105188740A (pt) |
| AU (1) | AU2014224594B2 (pt) |
| BR (1) | BR112015017463A8 (pt) |
| CA (1) | CA2898922A1 (pt) |
| EA (1) | EA201591657A1 (pt) |
| IL (1) | IL240902A0 (pt) |
| MX (1) | MX2015011623A (pt) |
| WO (1) | WO2014135689A2 (pt) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11033659B2 (en) | 2014-09-29 | 2021-06-15 | Board Of Regents Of The University Of Nebraska | Nanofiber structures and methods of synthesis and use thereof |
| CN107690333B (zh) * | 2015-06-10 | 2021-12-17 | 赢创运营有限公司 | 制备包含人凝血因子蛋白和乳酸聚合物的粉末的方法 |
| IL242984A0 (en) | 2015-12-08 | 2016-02-29 | Omrix Biopharmaceuticals Ltd | Thrombin microcapsules, their preparation and how to use them |
| US10159720B2 (en) | 2015-12-08 | 2018-12-25 | Omrix Biopharmaceuticals Ltd | Thrombin microcapsules, preparation and uses thereof |
| JP6926101B2 (ja) | 2015-11-06 | 2021-08-25 | エシコン・インコーポレイテッドＥｔｈｉｃｏｎ， Ｉｎｃ． | 圧密止血セルロース系凝集体 |
| CN107754005B (zh) | 2016-08-15 | 2021-06-15 | 广州倍绣生物技术有限公司 | 止血组合物及其制造方法 |
| US11413335B2 (en) * | 2018-02-13 | 2022-08-16 | Guangzhou Bioseal Biotech Co. Ltd | Hemostatic compositions and methods of making thereof |
| US20220111020A1 (en) * | 2016-08-15 | 2022-04-14 | Guangzhou Bioseal Biotech Co. Ltd. | Hemostatic compositions and methods of making thereof |
| US11318224B2 (en) | 2016-09-28 | 2022-05-03 | Board Of Regents Of The University Of Nebraska | Nanofiber structures and methods of use thereof |
| US11504341B2 (en) * | 2016-10-27 | 2022-11-22 | Egy-Nano Pharma, Lp | Nanotechnology-based hemostatic dressings |
| BR102017008027B1 (pt) * | 2017-04-18 | 2022-04-19 | Cristália Produtos Químicos Farmacêuticos Ltda | Processo de obtenção de biopolímero de fibrina, meios de aplicação do referido biopolímero de fibrina, e processo de aplicação do referido biopolímero de fibrina |
| US11738116B2 (en) | 2017-06-09 | 2023-08-29 | Board Of Regents Of The University Of Nebraska | Expanded nanofiber structures comprising electrospun nanofibers and a plurality of holes and methods of making and use thereof |
| US10194975B1 (en) * | 2017-07-11 | 2019-02-05 | Medtronic Advanced Energy, Llc | Illuminated and isolated electrosurgical apparatus |
| WO2019060393A1 (en) | 2017-09-19 | 2019-03-28 | Board Of Regents Of The University Of Nebraska | NANOFIBER STRUCTURES AND METHODS OF USE THEREOF |
| CN107727587B (zh) * | 2017-09-22 | 2020-06-19 | 宁波瑞源生物科技有限公司 | 一种抗凝血酶ⅲ测定试剂盒及其检测方法 |
| CN107875407A (zh) * | 2017-12-15 | 2018-04-06 | 天津梅花生物医药科技有限公司 | 一种新型的原料药无菌处理系统 |
| CN108709369A (zh) * | 2018-04-20 | 2018-10-26 | 大连工业大学 | 一种超声波喷雾冷冻干燥装置 |
| US20210212949A1 (en) * | 2018-04-23 | 2021-07-15 | Board Of Regents Of The University Of Nebraska | Nanofiber microspheres and methods os use thereof |
| CN109045362A (zh) * | 2018-09-11 | 2018-12-21 | 余碧芝 | 胶原蛋白微颗粒及其制备方法和应用 |
| JP2022554153A (ja) * | 2019-10-23 | 2022-12-28 | フィブリアント・ベスローテン・フェンノートシャップ | 抗微生物剤および抗微生物治療用アジュバントとしてのフィブリノゲン |
| CN110947349B (zh) * | 2019-12-24 | 2024-03-15 | 上海天晓环保工程有限公司 | 一种用于脱硫废水零排放的微波晶振干燥装置 |
| US11795189B2 (en) * | 2020-09-21 | 2023-10-24 | University Of Kentucky Research Foundation | Formulation and method for spray-drying D-tagatose |
| CN111956788A (zh) * | 2020-09-22 | 2020-11-20 | 上海利康瑞生物工程有限公司 | 一种猪源纤维蛋白原冻干制剂、制备工艺及其应用 |
| EP4217418A2 (de) * | 2020-09-24 | 2023-08-02 | Sphera Technology GmbH | Mehrkomponentensystem |
| CN112843326B (zh) * | 2021-01-26 | 2022-11-01 | 上海利康瑞生物工程有限公司 | 一种纤维蛋白粘合剂速效止血复合粉及其制备方法 |
| CN112972755B (zh) * | 2021-03-25 | 2022-07-05 | 哈尔滨瀚邦医疗科技有限公司 | 一种基于猪源纤维蛋白原和凝血酶的生物止血材料的制备方法 |
| WO2023017153A1 (en) * | 2021-08-13 | 2023-02-16 | Biotest Ag | Fibrinogen compositions and methods of preparation |
| CN113797325B (zh) * | 2021-09-29 | 2023-11-21 | 复旦大学 | 一种基于气流粉碎技术制备止血材料的方法 |
| CN118434458A (zh) | 2021-12-21 | 2024-08-02 | 奥姆里克斯生物药品有限公司 | 包含纤维蛋白原的制剂及其用途 |
| WO2023115427A1 (en) | 2021-12-23 | 2023-06-29 | Guangzhou Bioseal Biotech Co., Ltd. | Spray dried thrombin |
| US20230210958A1 (en) | 2021-12-30 | 2023-07-06 | Baxter International Inc. | Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit |
| TW202426067A (zh) * | 2022-09-30 | 2024-07-01 | 丹麥商弗羅桑醫療設備公司 | 止血組成物 |
| WO2024207176A1 (en) * | 2023-04-04 | 2024-10-10 | Guangzhou Bioseal Biotech Co., Ltd. | Hemostatic sealant powder for sealing leaks in tissues |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU702955B2 (en) * | 1996-05-17 | 1999-03-11 | Quadrant Healthcare (Uk) Limited | Microparticles and their use in wound therapy |
| DE19849589C1 (de) * | 1998-10-27 | 2000-06-15 | Glatt Process Technology Gmbh | Fibrin-Gewebekleber-Formulierung und Verfahren zu dessen Herstellung |
| US7572769B2 (en) * | 1998-12-23 | 2009-08-11 | Csl Behring Gmbh | Fibrin adhesive granulate and method for its preparation |
| US7927626B2 (en) * | 2003-08-07 | 2011-04-19 | Ethicon, Inc. | Process of making flowable hemostatic compositions and devices containing such compositions |
| US9827205B2 (en) * | 2008-12-12 | 2017-11-28 | Mallinckrodt Pharma Ip Trading D.A.C. | Dry powder fibrin sealant |
| GB0909129D0 (en) * | 2009-05-28 | 2009-07-01 | Quadrant Drug Delivery Ltd | Dry powder fibrin sealant |
| GB0909136D0 (en) * | 2009-05-28 | 2009-07-01 | Profibrix Bv | Dry powder composition |
| ES2593584T3 (es) * | 2009-05-28 | 2016-12-09 | Profibrix Bv | Sellante de fibrina en polvo seco |
| CN102724968A (zh) * | 2010-01-08 | 2012-10-10 | 普罗菲布瑞克斯公司 | 干粉血纤蛋白密封剂 |
| BR112012030455B1 (pt) * | 2010-06-01 | 2021-08-17 | Baxter Healthcare S.A. | Processo para fabricar uma composição hemostática seca e estável, recipiente acabado final, e, kit para administrar uma composição hemostática |
| RU2013155713A (ru) * | 2011-07-06 | 2015-08-20 | Профибрикс Бв | Составы для лечения ран |
-
2014
- 2014-03-07 JP JP2015560712A patent/JP2016510059A/ja active Pending
- 2014-03-07 BR BR112015017463A patent/BR112015017463A8/pt not_active Application Discontinuation
- 2014-03-07 EA EA201591657A patent/EA201591657A1/ru unknown
- 2014-03-07 AU AU2014224594A patent/AU2014224594B2/en not_active Ceased
- 2014-03-07 WO PCT/EP2014/054477 patent/WO2014135689A2/en active Application Filing
- 2014-03-07 CA CA2898922A patent/CA2898922A1/en not_active Abandoned
- 2014-03-07 MX MX2015011623A patent/MX2015011623A/es unknown
- 2014-03-07 CN CN201480012686.4A patent/CN105188740A/zh active Pending
- 2014-03-07 US US14/773,212 patent/US20160015792A1/en not_active Abandoned
- 2014-03-07 EP EP14709244.9A patent/EP2964252A2/en not_active Withdrawn
-
2015
- 2015-08-27 IL IL240902A patent/IL240902A0/en unknown
-
2019
- 2019-05-10 US US16/408,678 patent/US20190269764A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201591657A1 (ru) | 2015-12-30 |
| WO2014135689A2 (en) | 2014-09-12 |
| BR112015017463A8 (pt) | 2017-11-28 |
| US20160015792A1 (en) | 2016-01-21 |
| JP2016510059A (ja) | 2016-04-04 |
| AU2014224594A1 (en) | 2015-07-02 |
| CN105188740A (zh) | 2015-12-23 |
| MX2015011623A (es) | 2015-12-17 |
| US20190269764A1 (en) | 2019-09-05 |
| WO2014135689A3 (en) | 2014-10-30 |
| EP2964252A2 (en) | 2016-01-13 |
| AU2014224594B2 (en) | 2018-05-10 |
| IL240902A0 (en) | 2015-10-29 |
| CA2898922A1 (en) | 2014-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015017463A2 (pt) | formulação em pó | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112014008045A2 (pt) | benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas | |
| NZ629996A (en) | 2’- substituted carba-nucleoside analogs for antiviral treatment | |
| BR112014026493A2 (pt) | derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta | |
| BR112014026643A8 (pt) | derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta, seus usos e composição farmacêutica | |
| MX2015003653A (es) | Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj. | |
| BR112015019720B8 (pt) | Inibidores de (benzil-ciano-metil)-amidas de ácido 2-azabiciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c e composição farmacêutica | |
| BR112016005270A2 (pt) | compostos de aza-piridona, composições farmacêuticas e seus usos | |
| BR112014001880A2 (pt) | derivados de carboxamida e ureia contendo pirazol heteroaromáticos substituídos como ligantes de receptor vaniloide | |
| BR112014014184A2 (pt) | triazolopiridinas substituídas e seu uso como inibidores de ttk | |
| DOP2014000059A (es) | Derivados de estra1,3,5(10),16tetraen3carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| BR112015018491A2 (pt) | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv | |
| BR112016024571A2 (pt) | composto de 1,2,4-triazina dissubstituído | |
| BR112013005622A2 (pt) | heteroaril metil amidas | |
| BR112017018643A2 (pt) | "derivados de tetra-hidrotiazepina bicíclicos úteis, composição farmacêutica compreendendo os mesmos, seu uso, e método in vitro ou ex vivo para a produção de células imunes ativadas" | |
| BR112013000254A2 (pt) | derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2 | |
| ECSP15000868A (es) | Derivados de estra1,3,5(10),16tetraeno 3sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| BR112014018767A8 (pt) | Compostos de pirroldicarboxamidas fundidas e composição farmacêutica que os compreende | |
| BR112017012588A2 (pt) | compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta) | |
| BR112015027440A2 (pt) | DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO | |
| BR112015004523A2 (pt) | compostos de tetraciclina | |
| BR112015010271A8 (pt) | produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos | |
| BR112015015250A2 (pt) | derivados de pirrolidina, composições farmacêuticas e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: MALLINCKRODT PHARMA IP TRADING D.A.C. (IE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |